

1 **Mobile genetic element-encoded hypertolerance to copper protects *Staphylococcus***  
2 ***aureus* from killing by host phagocytes.**

3 Marta Zapotoczna<sup>1</sup>, Gus Peliccoli-Riboldi<sup>2</sup>, Ahmed M Moustafa<sup>3</sup>, Elizabeth Dickson<sup>4</sup>,  
4 Apurva Narechania<sup>5</sup>, Julie A. Morrissey<sup>6</sup>, Paul J. Planet<sup>3,5</sup>, Matthew T.G. Holden<sup>7</sup>, Kevin J.  
5 Waldron<sup>2</sup>, Joan A. Geoghegan<sup>1#</sup>

6

7 <sup>1</sup>Department of Microbiology, Moyne Institute of Preventive Medicine, School of Genetics  
8 and Microbiology, Trinity College Dublin, Dublin 2, Ireland.

9 <sup>2</sup>Institute for Cell & Molecular Biosciences, Faculty of Medical Sciences, Newcastle  
10 University, Framlington Place, Newcastle upon Tyne, NE2 4HH, United Kingdom.

11 <sup>3</sup>Pediatric Infectious Disease Division, Children's Hospital of Philadelphia, University of  
12 Pennsylvania, Abramson Pediatric Research Center, 1202A, 3615 Civic Center Blvd,  
13 Philadelphia, PA 19104, USA.

14 <sup>4</sup>Scottish MRSA Reference Service, Scottish Microbiology Reference Laboratories, Glasgow,  
15 United Kingdom.

16 <sup>5</sup>American Museum of Natural History, New York, NY, USA, 10024

17 <sup>6</sup>Department of Genetics, University of Leicester, University Road, Leicester, LE1 7RH,  
18 United Kingdom.

19 <sup>7</sup>School of Medicine, University of St Andrews, St Andrews, United Kingdom.

20

21

22 **Abstract**

23 Pathogens are exposed to toxic levels of copper during infection and copper tolerance  
24 may be a general virulence mechanism used by bacteria to resist host defences. In support of  
25 this, inactivation of copper-exporter genes has been found to reduce the virulence of bacterial  
26 pathogens *in vivo*. Here we investigate the role of copper-hypertolerance in methicillin  
27 resistant *Staphylococcus aureus*. We show that a copper-hypertolerance locus (*copB-mco*),  
28 carried on a mobile genetic element, is prevalent in a collection of invasive *S. aureus* strains  
29 and more widely among clonal complex 22, 30 and 398 strains. The *copB* and *mco* genes  
30 encode a copper efflux pump and a multicopper oxidase, respectively. Isogenic mutants  
31 lacking *copB* or *mco* had impaired growth in subinhibitory concentrations of copper. Transfer  
32 of a *copB-mco* encoding plasmid to a naive clinical isolate resulted in a gain of copper-  
33 hypertolerance and enhanced bacterial survival inside primed macrophages. The *copB* and  
34 *mco* genes were upregulated within infected macrophages and their expression was  
35 dependent on the copper sensitive operon repressor CsoR. Isogenic *copB* and *mco* mutants  
36 were impaired in their ability to persist intracellularly in macrophages and were less resistant  
37 to phagocytic killing in human blood than the parent strain. The importance of copper-  
38 regulated genes in resistance to phagocytic killing was further elaborated using mutants  
39 expressing a copper-insensitive variant of CsoR. Our findings suggest that the gain of mobile  
40 genetic elements carrying copper-hypertolerance genes contributes to the evolution of  
41 virulent strains of *S. aureus*, better equipped to resist killing by host immune cells.

42

43

## 44 **Introduction**

45           Methicillin resistant *Staphylococcus aureus* (MRSA) is a major problem for animal  
46 and human health and is considered a global high priority pathogen by the World Health  
47 Organisation (1). One reason why MRSA continues to be a problem is that it evolves rapidly  
48 by acquiring mobile genetic elements (MGE) such as plasmids. Many successful  
49 contemporary clones of MRSA carry copper resistance genes located on MGEs (2-6) but the  
50 contribution of copper resistance to the fitness and virulence of *S. aureus* has not yet been  
51 studied.

52 Copper is a key component of innate immune bactericidal defences and macrophages use  
53 copper to kill intracellular bacteria by actively importing it into the phagosome (7-10).  
54 Eukaryotic copper transport is facilitated by CTR1-mediated import into the cell and ATP7a-  
55 dependent transport into the phagolysosome (7, 11). Under aerobic conditions, excess copper  
56 is proposed to catalyze the production of hydroxyl radicals via the Fenton and Haber-Weiss  
57 reactions, which may cause oxidative damage to macromolecules due to their high redox  
58 potential. Copper toxicity (under all or perhaps only anoxic conditions) involves the  
59 formation of adventitious Cu(I)-thiolate bonds, thus damaging enzymes that functionally  
60 require free cysteines or disulfide bonds, such as iron sulfur cluster proteins (12, 13). The  
61 toxic properties of copper are harnessed by host phagocytes, such as macrophages (11, 14).  
62 Infection signalling, which involves elevated levels of interferon gamma (IFN $\gamma$ ) and a release  
63 of copper into the plasma, may trigger activation of macrophages and increased import of  
64 copper, which enhances killing of phagocytosed bacteria (7, 10, 15).

65           Pathogens have evolved mechanisms to counteract copper toxicity, mainly by limiting  
66 the copper concentration in their cytoplasm through efflux or sequestration by copper  
67 metallochaperones, metallothioneins or storage proteins (16). Almost all bacteria possess

68 genes that confer copper tolerance, from environmental bacteria isolated from black shale in  
69 copper-rich exploration regions (17) to human pathogens. Inactivation of copper-exporter  
70 genes has been shown *in vivo* to reduce the virulence of bacterial pathogens such as  
71 *Mycobacterium tuberculosis* (18), *Streptococcus pneumonia* (19), *Salmonella enterica* (10)  
72 and *Pseudomonas aeruginosa* (20). In some cases, the virulence defect has been shown to be  
73 due to the inability of these pathogens to resist copper-mediated killing within the  
74 macrophage phagosome (10). Data accumulated so far suggests that copper tolerance may be  
75 a general mechanism of virulence in bacteria and that pathogens are exposed to toxic levels  
76 of copper during infection (10, 18, 19, 21).

77 All *S. aureus* strains possess a conserved chromosomal operon, encoding the  
78 archetypal P<sub>1</sub>-type ATPase copper transporter CopA and a copper metallochaperone CopZ,  
79 that confers low level resistance to copper (Fig. 1A) (22). A copper-hypertolerance locus  
80 (*copB-mco*) has been described in some clinically relevant strains of *S. aureus*, carried either  
81 on a replicating plasmid or on a plasmid integrated into the chromosome (Fig. 1A) (2, 3, 5).  
82 The *copB* gene encodes a second copper exporting P<sub>1</sub>-type ATPase (CopB) and *mco* encodes  
83 a multicopper oxidase implicated in copper homeostasis and the oxidative stress response  
84 (23). A chromosomally-encoded homolog of the Cu-sensitive operon repressor (CsoR), first  
85 characterized in *M. tuberculosis* (24), was shown to control transcription of both operons in  
86 *S. aureus* (2).

87 Here we investigated the role of copper-hypertolerance in *S. aureus*. We found that  
88 the MGE-encoded *copB* and *mco* genes improved bacterial growth under copper stress and  
89 enhanced bacterial survival within macrophages and in whole human blood. Expression of  
90 *copB* and *mco* was detected by intracellular bacteria isolated from macrophages and CsoR  
91 was responsible for regulating expression of these genes *in vivo*. Finally we determined the  
92 extent of carriage of *copB* and *mco* genes in a collection of invasive *S. aureus* isolates from

- 93 European hospitals and in a more diverse collection of whole genome sequenced isolates
- 94 from around the world.

95 **Results**

96 **The tolerance of *S. aureus* to copper is enhanced by the *copB-mco* operons.**

97 The *copB-mco* copper-hypertolerance locus is carried either on a replicating plasmid  
98 or on a plasmid integrated into the chromosome (2, 3, 5). The role of MGE-encoded copper  
99 resistance genes in MRSA was studied using the *copB-mco* locus-carrying plasmid pSCBU,  
100 (3). Plasmid pSCBU, also known as P2-hm, was previously found to be carried by a  
101 population of MRSA CC22 bloodstream isolates from the UK and Ireland (3). For the  
102 purposes of this study, pSCBU was introduced into CC22 strain 14-2533T (Table S1). 14-  
103 2533T is a clinical isolate that is representative of the lineage where pSCBU was detected but  
104 it does not carry the plasmid. This strain was chosen as a clean and receptive host to study  
105 plasmid-conferred phenotypes.

106 The level of copper tolerance in 14-2533T carrying *copB* and *mco* genes on the  
107 replicating plasmid pSCBU was determined by measuring the minimal inhibitory  
108 concentrations (MICs) to copper salts (Table 1). Copper tolerance was the highest in 14-  
109 2533T carrying the replicating plasmid pSCBU (11 mM CuCl<sub>2</sub>), whereas the same strain  
110 without pSCBU had a lower MIC (6 mM). The individual contribution of *copB* and *mco* to  
111 copper tolerance was investigated by generating isogenic mutants carrying deletions in the  
112 copper tolerance genes on the plasmid pSCBU (pSCBUΔ*mco* and pSCBUΔ*copB*, Table S1  
113 and Fig. S1). Deletion of *mco* or *copB* resulted in an MIC decrease to 8 mM or 6 mM CuCl<sub>2</sub>,  
114 respectively (Table 1), indicating these genes are the main contributors to pSCBU-mediated  
115 copper tolerance.

116 The pSCBU plasmid also encodes a cadmium-efflux system (*cadA*), which is known  
117 to protect from intracellular accumulation of toxic Cd(II), Zn(II) and Co(II) (25). As a  
118 control, cadmium and zinc tolerance of the pSCBU variants was tested. We observed that

119 pSCBU conferred tolerance to cadmium and zinc (Table 1), which was unaffected by  
120 mutations in *copB* and *mco*, demonstrating that these genes do not influence resistance to  
121 these metals.

122

### 123 **CsoR binds to *copB* promoter DNA in a copper-dependent manner.**

124 The *S. aureus* copper-sensing transcriptional regulator (CsoR) was previously shown  
125 to negatively regulate both chromosomal and plasmid-encoded copper tolerance genes (2).  
126 Dissociation of CsoR from the GC-rich palindromic promoter regions has been shown to  
127 occur at two copper-regulated loci (*copA-copZ*, and *copB-mco*) in a copper-dependent  
128 manner (Fig 1A)(24). The *S. aureus* CsoR protein shares 24% amino acid sequence identity  
129 with CsoR from *Mycobacterium tuberculosis* (2). In *S. aureus*, residues Cys<sup>41</sup>, His<sup>66</sup> and  
130 Cys<sup>70</sup> are proposed to coordinate Cu(I) (26). Electrophoretic mobility shift assays (EMSA)  
131 assays performed anaerobically with recombinant CsoR and a ~250 bp DNA fragment  
132 representing the *copA* promoter ( $P_{copA}$ ) confirmed that the wild type CsoR repressor bound  
133 specifically to the *copA* promoter, whereas anaerobic incubation with Cu(I) prevented  
134 association of CsoR with the promoter DNA (Fig. 1B). In contrast, a CsoR variant carrying  
135 C41A/H66A/C70A substitutions (CHC variant herein) remained bound to the *copA* promoter  
136 DNA despite the presence of copper (Fig. 1C), suggesting it is unable to coordinate Cu(I) and  
137 thus to undergo its copper-dependent allosteric conformational change. Thus the CsoR CHC  
138 variant is insensitive to copper, and de-repression of CsoR-regulated genes will not occur in  
139 cells expressing this variant.

140 Since *copB* and *mco* genes are responsible for hypertolerance to copper in *S. aureus* (Table  
141 1), binding of CsoR to the *copB* and *mco* promoter regions was investigated. CsoR bound to  
142 DNA containing the sequence of the regions upstream of both *copA* and *copB* ( $P_{copB}$ ), but not  
143 that upstream of *mco* ( $P_{mco}$ ) (Fig. 1D), consistent with *copB* and *mco* being co-transcribed as

144 part of an operon, under the regulatory control of CsoR through binding to  $P_{copB}$ . There is no  
145 obvious CsoR binding sequence within the short intergenic region (14 bp) between *copB* and  
146 *mco* or in the 3' sequence of *copB* (2).

147

## 148 **Copper-hypertolerance enhances growth of *S. aureus* at subinhibitory concentrations of** 149 **copper**

150 To study the role of the copper sensitive operon repressor CsoR in copper tolerance,  
151 site-directed mutagenesis was carried out on the *csorR* genes on the chromosomes of 14-  
152 2533T (CC22) and the CC30 strain MRSA252 to introduce amino-acid substitutions  
153 (C41A/H66A/C70A) that generate the copper-insensitive CsoR variant (CsoR CHC) (Table  
154 S1).

155 The MRSA252 strain carries a chromosomally-integrated plasmid carrying the *copB*-  
156 *mco* locus and was more tolerant to copper (MIC = 8 mM) than its isogenic CsoR CHC  
157 mutant (5 mM) (Table 1), showing that CsoR represses the copper-tolerance phenotype in  
158 MRSA252. In contrast, the CsoR CHC variant expressing strain 14-2533T CHC (pSCBU)  
159 had a similar MIC (10 mM) to the parent strain 14-2553T (pSCBU) (11 mM) and an elevated  
160 MIC compared to the plasmid-negative 14-2553T host strain (6 mM). This could reflect that  
161 CsoR does not fully repress *copB-mco* expressed from multi-copy plasmids, as shown  
162 previously by Baker *et al.* using a *csorR*-deficient mutant (2). Thus these data may indicate  
163 that the single-copy chromosomally-integrated *copB-mco* operon is more efficiently  
164 repressed by apo-CsoR than the pSCBU replicating plasmid-encoded operon.

165 To determine if expression of the *copB* and *mco* genes had an impact on bacterial  
166 growth under copper stress, we monitored the growth of cultures in TSB containing a  
167 concentration of copper below the MIC for all strains and mutants (4 mM, Fig. 2). Strain 14-



168 2553T (pSCBU) grew faster and to a higher OD<sub>600</sub> in sub-inhibitory concentrations of copper  
169 than the same strain without the plasmid or the mutants deficient in *copB* or *mco* (Fig. 2A).  
170 The defect in growth was more pronounced for the *copB* mutant than for the *mco* mutant. In  
171 contrast the 14-2533T CsoR CHC (pSCBU) mutant had an identical growth profile to the  
172 wild-type strain carrying the plasmid, again suggesting that CsoR does not fully repress *copB*  
173 and *mco* expression from the pSCBU plasmid (Fig. 2A). There was no growth advantage  
174 observed for strains growing in TSB lacking copper (Fig. 2B) or when low ( $\mu$ M)  
175 concentrations of copper salts were added to the growth medium (data not shown). As a  
176 control, the growth of MRSA252 and the MRSA252 CsoR CHC mutant were compared in  
177 TSB containing a sub-inhibitory concentration of copper (4 mM, Fig. 2C). MRSA252 grew  
178 more quickly and reached a higher OD<sub>600</sub> than the copper-non-responsive regulatory mutant  
179 MRSA252 CsoR CHC, but not in media without copper (Fig. 2D). Transcription of *copB* and  
180 *mco* from pSCBU at sub-inhibitory concentrations of CuCl<sub>2</sub> was quantified by Reverse  
181 Transcription quantitative PCR (RT-qPCR, Fig. 2E). A 5- to 12-fold increase in the  
182 abundance of transcript was measured for *mco* and *copB* in TSB cultures supplemented with  
183 sub-inhibitory concentrations of CuCl<sub>2</sub> (4 mM), which confirmed that expression of *copB*-  
184 *mco* is copper-inducible. RNA transcripts of *mco* or *copB* were not detected in their  
185 respective deletion mutants (Fig. 2E, S1 & S3), as expected. Inducible copper-dependent  
186 expression of the other gene was detected in the mutants, showing that the respective gene  
187 deletions had not obstructed transcription of the other gene in this operon from the P<sub>*copB*</sub>  
188 promoter (Fig. 2E).

189

190 **Copper-hypertolerance genes increase *S. aureus* survival inside IFN $\gamma$ -activated**  
191 **macrophages.**

192 Copper has previously been shown to be critical for the killing of bacteria following  
193 phagocytosis (7). In the presence of copper, activated macrophages up-regulate expression of  
194 the copper importer, CTR1, and commence trafficking of the P-type ATPase ATP7A to the  
195 phagolysosomal membrane, which leads to an enhanced killing of intracellular bacteria (7,  
196 10).

197 To investigate whether bacterial tolerance to copper might influence the outcome for  
198 *S. aureus* following phagocytosis by macrophages, experiments were performed to quantify  
199 the survival of bacteria following phagocytosis. The murine macrophage cell line  
200 (RAW264.7) was activated with IFN $\gamma$  and treated with CuSO $_4$  to induce expression of the  
201 relevant copper transporters (ATP7A and CTR1), which was confirmed using RT-qPCR (Fig.  
202 S2) (7, 27). IFN $\gamma$ -activated macrophages internalised the wild-type and mutants at similar  
203 levels (data not shown). However, 3 h post-phagocytosis, intracellular levels of bacteria were  
204 significantly different between the strains. The 14-2533T (pSCBU) strain survived inside the  
205 macrophages at significantly higher levels than 14-2533T without the plasmid (Fig. 3A).  
206 Importantly, the copper-susceptible *copB* and *mco* mutants had a survival defect compared to  
207 their parent strain 14-2533T, suggesting that copper tolerance in *S. aureus* prevents killing by  
208 macrophages (Fig. 3A). The CsoR CHC mutant of 14-2533T (pSCBU) did not show a  
209 significant survival defect in macrophages (Fig. 3A), probably reflective of the fact that  
210 plasmid-encoded CsoR-regulated genes are not efficiently repressed in this strain (Table 1,  
211 Fig. 2), thus it behaves like the wild-type. In contrast the MRSA252 CsoR CHC mutant had  
212 a defect in macrophage survival (Fig. 3B).

213 To determine if the *copB* and *mco* genes are expressed by bacteria residing inside  
214 activated macrophages, RT-qPCR was performed using RNA obtained from intracellular  
215 bacteria at 3 h post infection. The relative transcription levels were compared between the  
216 wild-type strains and their isogenic CsoR CHC mutants. The *copB* and *mco* genes were found

217 to be 44- and 28-fold upregulated, respectively, in wild-type MRSA252 compared to  
218 MRSA252 CHC recovered from infected macrophages (Fig. 4A). This demonstrated that a)  
219 *copB* and *mco* are expressed by *S. aureus* inside the macrophage, and b) that this expression  
220 is CsoR-dependent within immune cells (Fig. 4A). The same experiment was carried out with  
221 14-2533T (pSCBU) and showed that *copB* and *mco* are expressed intracellularly in  
222 macrophages (Fig. 4B). However the increase in expression of *copB* and *mco* was much less  
223 for 14-2533T (pSCBU) than in the MRSA252 strain (Fig. 4B), which is consistent with  
224 susceptibility results (Table 1 and Fig. 2), indicating a weaker transcriptional control of CsoR  
225 over the plasmid-encoded genes compared to those that are carried on the chromosome of  
226 MRSA252.

227

## 228 **Copper-hypertolerance genes increase survival of *S. aureus* in whole human blood**

229 To determine whether the enhanced ability of *copB-mco* carrying strains to survive  
230 inside activated macrophages *in vitro* may be of relevance to infection of the human host, *ex*  
231 *vivo* infection studies were performed with whole human blood. Consistent with results  
232 obtained for intracellular survival within activated macrophages, copper-hypertolerant *S.*  
233 *aureus* 14-2533T (pSCBU) had an increased ability to survive in whole human blood  
234 compared to the 14-2533T strain without the pSCBU plasmid (Fig. 5A). This protection from  
235 killing in blood was due to copper resistance genes since the *mco* and *copB* mutants had a  
236 survival defect, similar to the plasmid-deficient 14-2533T strain (Fig. 5A). Protection from  
237 killing in blood could be attributed to resistance to phagocytic killing since incubation in the  
238 cell-free plasma fraction of the same blood under the same conditions yielded similar CFUs  
239 for wild-type and mutants (Fig. 5C).

240           The CsoR CHC mutant of MRSA252 had a significant defect in whole blood survival  
241 compared to the wild type but did not show a defect in growth in plasma (Fig. 5B, 5D). This  
242 showed that failure to de-repress CsoR-regulated genes (Fig. 1) impaired the ability of *S.*  
243 *aureus* to survive in blood. Together these results show the importance of copper  
244 hypertolerance genes for *S. aureus* to resist cellular killing in human blood.

245

246   **The *copB-mco* operon is carried by invasive *S. aureus* isolates and by strains belonging**  
247 **to CC22, CC30 and CC398.**

248           The prevalence of the *copB-mco* operon was investigated by interrogating the whole  
249 genome sequences (WGS) of 308 invasive *S. aureus* isolates (28) from hospitals across  
250 Europe. Mapping the *copB-mco* sequences against the WGS showed that this operon was  
251 present in 55 of the invasive isolates (17.9%). The *copB* and *mco* genes were carried by  
252 isolates from two major clonal complexes (CC) within the population; CC22 and CC30, and  
253 also a single CC8 isolate. All CC30 strains carried the *copB-mco* operon. The most prevalent  
254 sequence type (ST) in the CC30 population carrying *copB-mco* was ST30, but ST2868, ST36  
255 (EMRSA-16), ST2858, ST2864, ST2879, ST39, ST1829, ST2862, ST2881, and ST34  
256 isolates also carried *copB-mco*. Among the CC22 strains, 50% were found to carry the operon  
257 and all of them belonged to ST22 apart from one ST2877 isolate. In summary, *copB-mco*  
258 was found to be present in invasive *S. aureus* strains from across Europe but predominantly  
259 in isolates from two important clonal groups, CC22 and CC30 (28).

260           To further explore the presence of *copB* homologs as well as related copper tolerance  
261 genes, we interrogated all publicly available *S. aureus* genomes (Genbank; n=8037). While a  
262 conserved *copA* was found universally in 99.9% of all genomes, *copB* homologs were the  
263 second most prevalent copper tolerance gene at ca. 34.4% of all the genomes. The *copB* and

264 *mco* homologs were found mostly in CC22, CC30, and CC398, and only sporadically in other  
265 clonal complexes. To further characterize the distribution of genes in these three CCs, we  
266 constructed phylogenetic trees of each CC and mapped the presence and absence of each  
267 *copB* locus gene to each tree. Interestingly, the distributions of genes within each clade are  
268 strikingly different. For instance, CC30 genomes show a strong conservation of *copB* loci  
269 with very few predicted losses, whereas CC22 and CC398 have much more sporadic  
270 distributions that suggest multiple acquisitions and losses. This pattern could signal stronger,  
271 or more persistent, selection for *copB* loci in CC30 genomes as compared to CC22 and  
272 CC398, where selection may be weaker or intermittent. We also found evidence of a more  
273 diverse context to the copper hypertolerance genes than the original context in which they  
274 were found, i.e. the *copB-mco* operon, with an additional putative lipoprotein-encoding gene  
275 (4) (here called *copL*) frequently associated with the *copB-mco* operon in CC398 strains and  
276 less frequently in CC22 and CC30. These data indicate that the *copB-mco* copper  
277 hypertolerance genes are widely distributed in CC22, CC30 and CC398 and imply the  
278 presence of selection pressure for hypertolerance to copper.

279

280

281

## 282 Discussion

283 The connection between gain of copper tolerance and increased virulence of several human  
284 pathogens has been reported over recent years. Here we demonstrate that *S. aureus* employs  
285 copper hypertolerance to resist macrophage killing and to survive in whole human blood.  
286 Presumably, better survival in human blood is due to an increased resistance to killing by the  
287 cellular component because control experiments indicated that growth in blood plasma was  
288 not affected by copper resistance genes (Fig. 2). The increased resistance to phagocytic  
289 killing conferred by the *copB-mco* locus is likely to impact on the virulence potential of the  
290 bacterium *in vivo* and may provide a selective advantage to the pathogen. Importantly, *copB*  
291 and *mco* were expressed within infected macrophages, and the expression of these genes was,  
292 at least partially, dependent on expression of copper-responsive CsoR (Fig. 4). This provides  
293 indirect evidence that the *copB-mco* operon is expressed intracellularly in macrophages, in  
294 response to copper.

295 By studying the genome sequences of a collection of invasive isolates obtained from  
296 hospitals across Europe we determined the prevalence of *copB-mco* to be 17.9% of all  
297 isolates, emphasizing the clinical relevance of this locus (5, 28, 29). The *copB* and *mco* genes  
298 were carried by all isolates belonging to CC30, by 50% of isolates from CC22 and by a single  
299 CC8 isolate. The plasmid carrying the *copB-mco* operon was also recently reported to be  
300 carried by 43-70% of bloodstream infection isolates of *S. aureus* (mostly CC22) from the UK  
301 and Ireland sampled between 2001 and 2010 (3). There is evidence of extensive loss and gain  
302 of the pSCBU (p2-hm) plasmid (3) highlighting the mobility of the *copB-mco* locus within  
303 populations of *S. aureus*. The global significance of copper resistance in *S. aureus* was  
304 further highlighted by the widespread presence of *copB* and *mco* in CC22, CC30 and CC398  
305 strains (Fig. 6). Interestingly, CC398 are the most common CC found in European livestock.  
306 Previous studies have reported that 24.3% of livestock-associated MRSA carried the *copB*

307 gene (30). The use of copper compounds as feed supplements in animal husbandry may be  
308 selecting for the carriage of copper resistance genes by MRSA (31). Copper hypertolerance  
309 in *S. aureus* is likely to have more broad implications for human health since the dominant  
310 clone of community associated (CA)-MRSA in North America (USA300) and a closely  
311 related CA-MRSA clone found in South America (USA300-LV) both independently acquired  
312 a putative copper resistance locus as part of the arginine catabolic mobile element and the  
313 copper and mercury resistance element, respectively (4). In both cases the copper resistance  
314 loci are adjacent to the *SCCmec* element.

315 Consistent with a previous report (2), our data show that the *copB-mco* operon mediates  
316 copper hypertolerance in *S. aureus*. Disruption of the *copB* or *mco* genes inhibited the growth  
317 of *S. aureus* in sub-inhibitory concentrations of copper demonstrating that carriage of both of  
318 these genes provides a fitness advantage to *S. aureus* under copper stress. It can be therefore  
319 concluded that both CopB-mediated copper efflux, and the activity of Mco, play a role in  
320 protecting *S. aureus* from copper.

321 The CsoR repressor, which has been previously implicated in transcriptional regulation of  
322 *copA-copZ* and *copB-mco* (2), was shown here to control expression of *copA* and *copB-mco*  
323 in a copper-dependent manner by binding directly to the DNA sequence upstream of *copA*  
324 and *copB* but not of *mco* (Fig. 1). Inactivation of the putative Cu(I)-coordinating residues  
325 Cys41, His66, and Cys70 (CHC) disrupted copper-dependent de-repression of CsoR-  
326 regulated genes, showing that *S. aureus* CsoR uses the same mechanisms of copper  
327 coordination as previously described by Liu *et al.* (24) for CsoR from *M. tuberculosis*.  
328 Although continued association of CsoR CHC with the *copA* and *copB* promoter DNA was  
329 confirmed by EMSA using recombinant proteins (Fig. 2), repression of the copper tolerance  
330 phenotype by the CsoR CHC variant was only completely effective in live bacteria with the  
331 chromosomally-encoded *copB-mco* operon (strain MRSA252 CHC). In contrast, the CHC

332 mutant of 14-2533T (pSCBU) did not completely lose the copper hypertolerance phenotype  
333 shown by the parent strain carrying a wild-type copy of the *csoR* gene (Table 1, Fig. 2 and 4),  
334 showing that CsoR does not fully repress copper hypertolerance conferred by this plasmid. It  
335 may be that the pSCBU plasmid (are therefore *copB-mco*) are present in multiple copies, or  
336 due to poor diffusion of CsoR to the plasmid-located genes.

337           Horizontal gene transfer represents a major driving force in the evolution of *S. aureus*  
338 (32). This study provides important new insights into the contribution of MGE-encoded  
339 copper hypertolerance loci to the resistance of *S. aureus* to innate immune defenses. Due to  
340 the potential for MGEs to transmit rapidly in populations of *S. aureus*, our study shows that  
341 the spread of copper-hypertolerance loci could have important implications for the evolution  
342 of *S. aureus* as a pathogen.

343

344



## 345 **Materials and methods**

### 346 **Bacterial strains and growth conditions**

347 *S. aureus* strains used in the study are listed in Table S1. Bacteria were grown on  
348 tryptic soy agar (TSA) plates or in liquid cultures in either tryptic soy broth (TSB) or RPMI-  
349 1640 at 37°C with shaking (200 rpm). To select for pSCBU-carrying strains, TSA was  
350 supplemented with CdCl<sub>2</sub> at 1 mM. Growth curves were obtained using microtiter plates in  
351 TSB containing copper salts (either CuCl<sub>2</sub> or CuSO<sub>4</sub>). For macrophage and whole blood  
352 survival assays bacterial strains were cultured in RPMI-1640 in aerated 50 mL falcon tubes at  
353 37°C with shaking (200 rpm).

354

### 355 **Construction of mutations in plasmid-borne and chromosomally integrated *copB* &** 356 ***mco*.**

357 Plasmid pSCBU was extracted from strain SASCBU26 (33) and used to transform  
358 strain 14-2533T (Table S1). Mutations in *S. aureus*, including deletions in the native plasmid  
359 pSCBU (Table S1; Fig. S1), were introduced using pIMAY (34). Plasmid deletions in the  
360 copper tolerance genes, pSCBUΔ*mco* and pSCBUΔ*copB*, were isolated in the 14-2533T  
361 (CC22) background (Table S1, Fig. S1). It was necessary to purify and reintroduce each  
362 validated mutated plasmid into a clean background in order to eliminate a mixed population  
363 containing a mutated and wild type copy of this multi-copy plasmid (2).

364

### 365 **Susceptibility testing**

366 Minimal inhibitory concentrations (MICs) of soluble metal salts were determined  
367 using the standard broth microdilution method according to the guidelines by Clinical and

368 Laboratory Standards Institute (CLSI). The lowest concentration of a compound showing no  
369 visible growth was recorded as the MIC.

370

### 371 **Production and purification of recombinant CsoR**

372 The wild type *csoR* gene was amplified (Table S2) from *S. aureus* genomic DNA and  
373 cloned into pGEM-T (Promega). An internal NdeI site was mutated silently by QuikChange  
374 (Stratagene), and then *csoR* was sub-cloned into vector pET29a via NdeI/BamHI digestion  
375 and ligation. The *csoR* CHC mutant gene was amplified from the respective pIMAY  
376 construct. Constructs were confirmed by sequencing (GATC Biotech).

377 BL21(DE3) cells transformed with the resulting vectors, pET29a-CsoR or pET29a-  
378 CsoR-CHC, were cultured in lysogeny broth (LB) at 37°C with 180 rpm orbital shaking, and  
379 protein expression induced at OD<sub>600</sub> ~ 0.6 with addition of 1 mM isopropyl β-D-1-  
380 thiogalactopyranoside (IPTG), followed by further incubation at 30°C for 5 h. Cells were  
381 harvested, washed, resuspended in 25 mM Tris, pH 7.5, 15 mM dithiothreitol (DTT),  
382 containing protease inhibitor cocktail (Sigma) and lysed by sonication.

383 The supernatant was clarified by centrifugation and filtration, and purified by anion  
384 exchange chromatography on a 5 mL HiTrap Q HP column and an Akta purifier (GE  
385 Healthcare). Protein was eluted with a linear [NaCl] gradient (0-1 M NaCl), and CsoR-  
386 containing fractions (assessed by SDS-PAGE) subsequently concentrated on a 1 mL Heparin  
387 column (GE Healthcare) eluted with 1 M NaCl. This fraction was incubated overnight at 4°C  
388 with 10 mM EDTA and 20 mM tris(2-carboxyethyl)phosphine (TCEP), before resolution on  
389 a Superdex 75 16/600 column in 25 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid  
390 (Hepes), pH 7.5, 200 mM NaCl, 15 mM DTT.

391

### 392 **EMSA**

393 *S. aureus* MRSA252 genomic DNA was used to PCR amplify the putative promoter  
394 regions (i.e. the ~200 bp upstream of the start codon) of *copA*, *copB*, and *mco* (Table S2),  
395 which were cloned into vector pGEM-T, confirmed by sequencing. The promoter fragments  
396 (plus ~100 bp of flanking sequence from pGEM-T) were produced by PCR amplification  
397 from these pGEM-T constructs, plus a negative control fragment containing only the pGEM-  
398 T sequences. These PCR products were purified, and used in EMSA assays.

399 EMSAs were performed by incubating fully reduced (as determined with Elman's  
400 reagent) recombinant CsoR variants (0-100  $\mu$ M) with the respective promoter DNA plus the  
401 negative control DNA (both 0.1  $\mu$ M) in 20 mM Hepes, pH 7.0, 100 mM NaCl, 100 ng/ $\mu$ L  
402 poly dI-dC (Sigma), 1 mM DTT, 0.4 mg/mL bovine serum albumin (BSA) at room  
403 temperature for 30 min. All incubations were performed anaerobically inside an N<sub>2</sub>  
404 atmosphere glovebox ([O<sub>2</sub>] < 5 ppm – Belle Technology), and Cu(I)-CsoR was prepared by  
405 anaerobically incubating protein for 10 min with 1 mole equivalent of Cu(I) prepared as  
406 previously described (35). After incubation, samples were resolved on 6% acrylamide (w/v)  
407 native PAGE for 60-80 min at 82 V, and stained with 10% SYBR Safe solution (Invitrogen)  
408 for 20 min.

409

#### 410 **RNA extraction**

411 **To isolate RNA from *S. aureus***, bacterial cultures were grown in 20 mL TSB with or  
412 without copper salts (as indicated) to an OD<sub>600</sub> ~ 0.6. Cultures were suspended in  
413 phenol/ethanol (5:95%) mixture and incubated on ice for 1 h before pelleting the cells by  
414 centrifugation. At this step pellets were either stored at -70°C or subjected to total RNA  
415 extraction. To extract RNA, pellet(s) were gently suspended in 1 mL of TRIZOL following  
416 lysis using FastPrep® Lysing beads (3×45 s, 2 min intervals on ice). Aqueous lysate was then  
417 mixed with chloroform (2:1) in Phase Lock Gel to separate the RNA-containing aqueous

418 upper layer from the high density organic lower phase. The upper phase was precipitated with  
419 isopropanol (1:1) following ultracentrifugation at top speed for 30 min. The pellet was  
420 washed with 70% (v/v) ethanol and centrifuged. Supernatant was removed and the RNA  
421 pellet dried.

422 **RNA isolation from macrophages** was performed using a modified TRIZOL-based  
423 method. RAW264.7 cells were lysed directly in the culture dish by adding 12 mL of TRIZOL  
424 per T-175 cm<sup>2</sup> flasks and scraping the cells. Chloroform was added to the suspension at 0.2  
425 mL per 1 mM of TRIZOL reagent. Samples were immediately vortexed and incubated in RT  
426 for 2-3 min. Following centrifugation at 12,000 g for 15 min at 4 °C the mixture separated  
427 into layers and the upper aqueous layer was collected, precipitated with 0.5 mL isopropanol  
428 per 1mL of TRIZOL, incubated in RT for 10 min and centrifuged at 12,000 g for 10 min at 4  
429 °C. Obtained RNA pellet was washed once with 75% ethanol (adding at least 1mL per 1mL  
430 of TRIZOL).

431 **To isolate RNA from intracellular *S. aureus***, a combination of the above methods  
432 was used. Firstly, an infection was performed in T-175 cm<sup>2</sup> flask following  
433 gentamycin/lysostaphin killing of extracellular bacteria and monolayer washing. Cells were  
434 then lysed with TRIZOL, like described above. Centrifugation at 4,000 g for 20 min was  
435 performed to separate the bacteria into a pellet. RNA from the bacteria- containing pellet and  
436 macrophage RNA –containing suspension were extracted using respective methods.

437 All air-dried pellets were dissolved in RNase-free molecular grade water and their  
438 stability and purity was checked by gel electrophoresis and the concentration determined  
439 using a Thermo Scientific Nanodrop spectrophotometer.

440

441 **RT-PCR**

442 RNA was digested by DNase I treatment (Qiagen) according to manufacturer's  
443 instructions and quantified using Nanodrop Spectrophotometer and the integrity assessed by  
444 electrophoresis. RNA was reverse transcribed to cDNA using High Capacity RNA-to-cDNA  
445 Kit (Applied Biosystems). RT-qPCR was performed using the Power SYBR Green PCR  
446 Master Mix (Applied Biosystems). The relative levels of gene expression in the treated cells  
447 and the non-treated controls were calculated by relative quantification using *gyrB* as the  
448 reference gene and using the primers in Table S2. All samples were amplified in triplicate  
449 and the data analysis was carried out using the Step One Software (Applied Biosystems).  
450 Genomic DNA was isolated from cultured macrophages as described previously  
451 ([http://cancer.ucsf.edu/\\_docs/cores/array/protocols/dna\\_cell\\_culture.pdf](http://cancer.ucsf.edu/_docs/cores/array/protocols/dna_cell_culture.pdf)). Isolated DNA was  
452 used as a template to generate standard curve.

453

#### 454 **Macrophage survival assays**

455 Murine macrophage cell line (RAW264.7) was cultured in DMEM 10% (v/v) FBS.  
456 To generate monolayers  $2 \times 10^6$  cells per mL were seeded in in 24-well plates (500  $\mu$ L per  
457 well) and incubated for 24 h in serum-free DMEM supplemented with  $\text{CuSO}_4$  (40  $\mu$ M) and  
458 mouse  $\text{IFN}\gamma$  (50  $\mu$ g/mL) for 18 h at 37°C, 5%  $\text{CO}_2$ . Immediately before the infection,  
459 RAW264.7 monolayers were washed with ice-cold DMEM alone. *S. aureus* strains were  
460 cultured in RPMI-1640. Immediately before the experiment bacteria were washed twice with  
461 DMEM and adjusted to an  $\text{OD}_{600}$  of 0.05 (ca.  $2 \times 10^7$  of CFU per mL) in DMEM and  
462 inoculated into the monolayers for 30 min. The monolayers were subsequently washed and  
463 extracellular bacteria were killed by treatment with gentamicin (200  $\mu$ g/mL) & lysostaphin  
464 (100  $\mu$ g/mL) for 30 min. Monolayers were then washed and lysed with ice-cold water at time  
465 point 0 (T0) and after additional 3 h incubation (T3) to determine the survival rates

466 (CFU/mL). Lysates were plated on agar and CFUs were counted to determine numbers of  
467 viable bacteria.

468

### 469 **Human blood survival assays**

470 The method for quantification of *S. aureus* in human blood was derived from Visai *et*  
471 *al.* (36). Briefly, *S. aureus* variants were grown in RPMI-1640 to stationary phase and  
472 diluted in RPMI and 25  $\mu$ L (containing ca.  $1 \times 10^4$  CFU/mL) was added to 475 mL fresh blood  
473 obtained from healthy human volunteers that had been treated with 50 mg/mL of hirudin  
474 anticoagulant (Refludan, Pharmion). Tubes were incubated at 37°C with gentle rocking, and  
475 after 3 h serial dilutions were plated to determine the CFU/mL of viable bacteria. In parallel,  
476 an equal inoculum was incubated with cell-free plasma derived from the same donor's blood.  
477 Bacterial numbers in plasma were quantified (CFU/mL) at 3 h time point and % survival of  
478 the original inoculum was determined. Ethical approval for the use of human blood was  
479 obtained from the TCD Faculty of Health Sciences ethics committee.

480

### 481 **Phylogenetic Matrix Construction and Gene Presence Absence**

482 All preassembled genomes from public databases for CC22, CC30 and CC398  
483 (n=1075, 320 and 707, respectively) were used for whole-genome alignment with reference  
484 to the *S. aureus* N315 genome, using the NUCmer and show-snps utilities of MUMmer  
485 (<http://mummer.sourceforge.net>) (37). The *S. aureus* genomes were assigned sequence types  
486 (ST) and CC by the *S. aureus* MLST typing scheme <https://pubmlst.org/saureus/> sited at the  
487 University of Oxford (38) using the MLST typing perl script v. 2.9 for contigs  
488 (<https://github.com/tseemann/mlst>) and thereafter membership in each CC was determined by  
489 clade membership in a large (n=8037; unpublished data) *S. aureus* dataset composed of all

490 publically available preassembled genomes. All regions from the reference genome annotated  
491 as mobile genetic elements were excluded. We also applied a mask that excluded repetitive  
492 sequences from the reference genome that were >80% identical over at least 100 nucleotides  
493 to other genomic loci, based on pairwise MegaBLAST-based analysis (39). For each CC, a  
494 Maximum likelihood phylogeny was constructed with RAxML v8.2.11 (40) using an  
495 ascertainment bias correction and the general time-reversible (GTR) substitution model (41)  
496 accounting for among-site rate heterogeneity using the  $\Gamma$  distribution and four rate categories  
497 (42) (ASC\_GTRGAMMA model) for 100 individual searches with maximum parsimony  
498 random-addition starting trees. Node support was evaluated with 100 nonparametric  
499 bootstrap pseudoreplicates (43).

500 We used the *copA*, *copB* and *copL* genes from TCH1516 and *mco* from CA12 to search for  
501 closely related genes in the genus *Staphylococcus* in GenBank (wgs and nr databases, 9222  
502 genomes as of 08/16/2017), using BLAST (tblastx with a cutoff value  $1e-130$  for *copA*, *copB*  
503 and *mco* while  $1e-90$  for *copL*) (44). The four genes were mapped to the three trees as high-  
504 quality circular representations using GraPhlAn software tool  
505 (<https://bitbucket.org/nsegata/graphlan/>). The richness of the colour shows the percentage  
506 similarity with the seed sequence used.

507

## 508 **Statistics**

509 The data presented by this study represent the means  $\pm$  SD of three experiments  
510 unless otherwise stated. Statistical significance was assessed using two-way ANOVA and  
511 indicated as \* for  $P < 0.05$ , \*\* for  $P < 0.001$  and \*\*\* for  $P < 0.0001$ , unless otherwise stated.

512

513 **Funding Information**

514 MZ and JG were supported by funding from the European Union's Horizon 2020 research  
515 and innovation programme under grant agreement no. 634588. KJW was supported by a Sir  
516 Henry Dale Fellowship funded by the Wellcome Trust and the Royal Society  
517 (098375/Z/12/Z). GPR was funded by a CAPES Science Without Borders scholarship (BEX  
518 2445/13-1). MTGH is funded by the Chief Scientist Office through the Scottish Infection  
519 Research Network, a part of the SHAIPI consortium (Grant Reference Number SIRN/10).

520

521

522



## References

523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547

1. **WHO.** 2017. Prioritization of pathogens to guide discovery, research and development of new antibiotics for drug resistant bacterial infections, including tuberculosis World Health Organization.
2. **Baker J, Sengupta M, Jayaswal RK, Morrissey JA.** 2011. The *Staphylococcus aureus* CsoR regulates both chromosomal and plasmid-encoded copper resistance mechanisms. *Environ Microbiol* **13**:2495-2507.
3. **Jamrozy D, Coll F, Mather AE, Harris SR, Harrison EM, MacGowan A, Karas A, Elston T, Estee Torok M, Parkhill J, Peacock SJ.** 2017. Evolution of mobile genetic element composition in an epidemic methicillin-resistant *Staphylococcus aureus*: temporal changes correlated with frequent loss and gain events. *BMC Genomics* **18**:684.
4. **Planet PJ, Diaz L, Kolokotronis SO, Narechania A, Reyes J, Xing G, Rincon S, Smith H, Panesso D, Ryan C, Smith DP, Guzman M, Zurita J, Sebra R, Deikus G, Nolan RL, Tenover FC, Weinstock GM, Robinson DA, Arias CA.** 2015. Parallel Epidemics of Community-Associated Methicillin-Resistant *Staphylococcus aureus* USA300 Infection in North and South America. *J Infect Dis* **212**:1874-1882.
5. **Holden MT, Feil EJ, Lindsay JA, Peacock SJ, Day NP, Enright MC, Foster TJ, Moore CE, Hurst L, Atkin R, Barron A, Bason N, Bentley SD, Chillingworth C, Chillingworth T, Churcher C, Clark L, Corton C, Cronin A, Doggett J, Dowd L, Feltwell T, Hance Z, Harris B, Hauser H, Holroyd S, Jagels K, James KD, Lennard N, Line A, Mayes R, Moule S, Mungall K, Ormond D, Quail MA, Rabinowitsch E, Rutherford K, Sanders M, Sharp S, Simmonds M, Stevens K, Whitehead S, Barrell BG, Spratt BG, Parkhill J.** 2004. Complete genomes of two

- 548 clinical *Staphylococcus aureus* strains: evidence for the rapid evolution of virulence  
549 and drug resistance. Proc Natl Acad Sci U S A **101**:9786-9791.
- 550 6. **Gomez-Sanz E, Kadlec K, Fessler AT, Zarazaga M, Torres C, Schwarz S.** 2013.  
551 Novel erm(T)-carrying multiresistance plasmids from porcine and human isolates of  
552 methicillin-resistant *Staphylococcus aureus* ST398 that also harbor cadmium and  
553 copper resistance determinants. Antimicrob Agents Chemother **57**:3275-3282.
- 554 7. **White C, Lee J, Kambe T, Fritsche K, Petris MJ.** 2009. A role for the ATP7A  
555 copper-transporting ATPase in macrophage bactericidal activity. J Biol Chem  
556 **284**:33949-33956.
- 557 8. **Hodgkinson V, Petris MJ.** 2012. Copper homeostasis at the host-pathogen interface.  
558 J Biol Chem **287**:13549-13555.
- 559 9. **Djoko KY, Ong CL, Walker MJ, McEwan AG.** 2015. The Role of Copper and Zinc  
560 Toxicity in Innate Immune Defense against Bacterial Pathogens. J Biol Chem  
561 **290**:18954-18961.
- 562 10. **Ladomersky E, Khan A, Shanbhag V, Cavet JS, Chan J, Weisman GA, Petris**  
563 **MJ.** 2017. Host and Pathogen Copper-Transporting P-Type ATPases Function  
564 Antagonistically during *Salmonella* Infection. Infect Immun **85**.
- 565 11. **Festa RA, Thiele DJ.** 2012. Copper at the front line of the host-pathogen battle. PLoS  
566 Pathog **8**:e1002887.
- 567 12. **Macomber L, Imlay JA.** 2009. The iron-sulfur clusters of dehydratases are primary  
568 intracellular targets of copper toxicity. Proc Natl Acad Sci U S A **106**:8344-8349.
- 569 13. **Gaupp R, Ledala N, Somerville GA.** 2012. Staphylococcal response to oxidative  
570 stress. Front Cell Infect Microbiol **2**:33.

- 571 14. **Achard ME, Stafford SL, Bokil NJ, Chartres J, Bernhardt PV, Schembri MA,**  
572 **Sweet MJ, McEwan AG.** 2012. Copper redistribution in murine macrophages in  
573 response to *Salmonella* infection. *Biochem J* **444**:51-57.
- 574 15. **Hordyjewska A, Popiolek L, Kocot J.** 2014. The many "faces" of copper in  
575 medicine and treatment. *Biometals* **27**:611-621.
- 576 16. **Gold B, Deng H, Bryk R, Vargas D, Eliezer D, Roberts J, Jiang X, Nathan C.**  
577 2008. Identification of a copper-binding metallothionein in pathogenic mycobacteria.  
578 *Nat Chem Biol* **4**:609-616.
- 579 17. **Dziewit L, Pyzik A, Szuplewska M, Matlakowska R, Mielnicki S, Wibberg D,**  
580 **Schluter A, Puhler A, Bartosik D.** 2015. Diversity and role of plasmids in  
581 adaptation of bacteria inhabiting the Lubin copper mine in Poland, an environment  
582 rich in heavy metals. *Front Microbiol* **6**:152.
- 583 18. **Ward SK, Abomoelak B, Hoye EA, Steinberg H, Talaat AM.** 2010. CtpV: a  
584 putative copper exporter required for full virulence of *Mycobacterium tuberculosis*.  
585 *Mol Microbiol* **77**:1096-1110.
- 586 19. **Johnson MD, Kehl-Fie TE, Klein R, Kelly J, Burnham C, Mann B, Rosch JW.**  
587 2015. Role of copper efflux in pneumococcal pathogenesis and resistance to  
588 macrophage-mediated immune clearance. *Infect Immun* **83**:1684-1694.
- 589 20. **Schwan WR, Warrenner P, Keunz E, Stover CK, Folger KR.** 2005. Mutations in  
590 the *cueA* gene encoding a copper homeostasis P-type ATPase reduce the  
591 pathogenicity of *Pseudomonas aeruginosa* in mice. *Int J Med Microbiol* **295**:237-242.
- 592 21. **Neyrolles O, Mintz E, Catty P.** 2013. Zinc and copper toxicity in host defense  
593 against pathogens: *Mycobacterium tuberculosis* as a model example of an emerging  
594 paradigm. *Front Cell Infect Microbiol* **3**:89.

- 595 22. **Sitthisak S, Knutsson L, Webb JW, Jayaswal RK.** 2007. Molecular  
596 characterization of the copper transport system in *Staphylococcus aureus*.  
597 Microbiology **153**:4274-4283.
- 598 23. **Sitthisak S, Howieson K, Amezola C, Jayaswal RK.** 2005. Characterization of a  
599 multicopper oxidase gene from *Staphylococcus aureus*. Appl Environ Microbiol  
600 **71**:5650-5653.
- 601 24. **Liu T, Ramesh A, Ma Z, Ward SK, Zhang L, George GN, Talaat AM,**  
602 **Sacchettini JC, Giedroc DP.** 2007. CsoR is a novel *Mycobacterium tuberculosis*  
603 copper-sensing transcriptional regulator. Nat Chem Biol **3**:60-68.
- 604 25. **Tynecka Z, Gos Z, Zajac J.** 1981. Energy-dependent efflux of cadmium coded by a  
605 plasmid resistance determinant in *Staphylococcus aureus*. J Bacteriol **147**:313-319.
- 606 26. **Grossoehme N, Kehl-Fie TE, Ma Z, Adams KW, Cowart DM, Scott RA, Skaar**  
607 **EP, Giedroc DP.** 2011. Control of copper resistance and inorganic sulfur metabolism  
608 by paralogous regulators in *Staphylococcus aureus*. J Biol Chem **286**:13522-13531.
- 609 27. **Watkins RL, Zurek OW, Pallister KB, Voyich JM.** 2013. The SaeR/S two-  
610 component system induces interferon-gamma production in neutrophils during  
611 invasive *Staphylococcus aureus* infection. Microbes Infect **15**:749-754.
- 612 28. **Aanensen DM, Feil EJ, Holden MT, Dordel J, Yeats CA, Fedosejev A, Goater R,**  
613 **Castillo-Ramirez S, Corander J, Colijn C, Chlebowicz MA, Schouls L, Heck M,**  
614 **Pluister G, Ruimy R, Kahlmeter G, Ahman J, Matuschek E, Friedrich AW,**  
615 **Parkhill J, Bentley SD, Spratt BG, Grundmann H, European SRLWG.** 2016.  
616 Whole-Genome Sequencing for Routine Pathogen Surveillance in Public Health: a  
617 Population Snapshot of Invasive *Staphylococcus aureus* in Europe. MBio **7**.
- 618 29. **Grundmann H, Aanensen DM, van den Wijngaard CC, Spratt BG, Harmsen D,**  
619 **Friedrich AW, European Staphylococcal Reference Laboratory Working G.**

- 620 2010. Geographic distribution of *Staphylococcus aureus* causing invasive infections  
621 in Europe: a molecular-epidemiological analysis. PLoS Med **7**:e1000215.
- 622 30. **Argudin MA, Butaye P.** 2016. Dissemination of metal resistance genes among  
623 animal methicillin-resistant coagulase-negative Staphylococci. Res Vet Sci **105**:192-  
624 194.
- 625 31. **Yazdankhah S, Rudi K, Bernhoft A.** 2014. Zinc and copper in animal feed -  
626 development of resistance and co-resistance to antimicrobial agents in bacteria of  
627 animal origin. Microb Ecol Health Dis **25**.
- 628 32. **Lindsay JA.** 2014. *Staphylococcus aureus* genomics and the impact of horizontal  
629 gene transfer. Int J Med Microbiol **304**:103-109.
- 630 33. **Harris SR, Cartwright EJ, Torok ME, Holden MT, Brown NM, Ogilvy-Stuart**  
631 **AL, Ellington MJ, Quail MA, Bentley SD, Parkhill J, Peacock SJ.** 2013. Whole-  
632 genome sequencing for analysis of an outbreak of methicillin-resistant *Staphylococcus*  
633 *aureus*: a descriptive study. Lancet Infect Dis **13**:130-136.
- 634 34. **Monk IR, Shah IM, Xu M, Tan MW, Foster TJ.** 2012. Transforming the  
635 untransformable: application of direct transformation to manipulate genetically  
636 *Staphylococcus aureus* and *Staphylococcus epidermidis*. MBio **3**.
- 637 35. **Vita N, Platsaki S, Basle A, Allen SJ, Paterson NG, Crombie AT, Murrell JC,**  
638 **Waldron KJ, Dennison C.** 2015. A four-helix bundle stores copper for methane  
639 oxidation. Nature **525**:140-143.
- 640 36. **Visai L, Yanagisawa N, Josefsson E, Tarkowski A, Pezzali I, Rooijackers SH,**  
641 **Foster TJ, Speziale P.** 2009. Immune evasion by *Staphylococcus aureus* conferred  
642 by iron-regulated surface determinant protein IsdH. Microbiology **155**:667-679.

- 643 37. **Kurtz S, Phillippy A, Delcher AL, Smoot M, Shumway M, Antonescu C,**  
644 **Salzberg SL.** 2004. Versatile and open software for comparing large genomes.  
645 *Genome Biol* **5**:R12.
- 646 38. **Jolley KA, Maiden MC.** 2010. BIGSdb: Scalable analysis of bacterial genome  
647 variation at the population level. *BMC Bioinformatics* **11**:595.
- 648 39. **Morgulis A, Coulouris G, Raytselis Y, Madden TL, Agarwala R, Schaffer AA.**  
649 2008. Database indexing for production MegaBLAST searches. *Bioinformatics*  
650 **24**:1757-1764.
- 651 40. **Stamatakis A.** 2014. RAxML version 8: a tool for phylogenetic analysis and post-  
652 analysis of large phylogenies. *Bioinformatics* **30**:1312-1313.
- 653 41. **Lanave C, Preparata G, Saccone C, Serio G.** 1984. A new method for calculating  
654 evolutionary substitution rates. *J Mol Evol* **20**:86-93.
- 655 42. **Yang Z.** 1994. Maximum likelihood phylogenetic estimation from DNA sequences  
656 with variable rates over sites: approximate methods. *J Mol Evol* **39**:306-314.
- 657 43. **Felsenstein J.** 1985. Confidence Limits on Phylogenies: An Approach Using the  
658 Bootstrap. *Evolution* **39**:783-791.
- 659 44. **Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ.** 1990. Basic local  
660 alignment search tool. *J Mol Biol* **215**:403-410.

661

662

663

664 **Figure legends**

665 **Figure 1.** Electrophoretic mobility shift assay analysis of recombinant CsoR variants binding  
666 to the putative promoters upstream of *copA* ( $P_{copA}$ ), *copB* ( $P_{copB}$ ) and *mco* ( $P_{mco}$ ). A)  
667 Schematic representation of *copA-copZ* & *copB-mco* operons with putative promoter  
668 sequences. B-D) Recombinant wildtype CsoR<sub>WT</sub> or the CsoR<sub>CHC</sub> mutant (CsoR  
669 C41A/H66A/C70A) were purified and tested for binding to PCR products containing the  
670 DNA sequences (~200 bp) upstream of the respective start codon, and a control DNA  
671 fragment of non-specific DNA sequence (nsDNA). B) Incubation of  $P_{copA}$  DNA with wild  
672 type apo-CsoR, but not Cu(I)-CsoR, retards the migration of  $P_{copA}$ . C) CsoR CHC retards  
673 migration of  $P_{copA}$  in both the presence and absence of Cu(I). D) CsoR retards migration of  
674  $P_{copA}$  and  $P_{copB}$  but not of  $P_{mco}$ .

675 **Figure 2.** Enhanced growth in subinhibitory concentrations of copper chloride requires  
676 expression of copper tolerance genes. Growth of *S. aureus* 14-2533T and MRSA252 variants  
677 was measured in TSB supplemented with sub-inhibitory (4 mM) concentrations of copper  
678 chloride (A, C) or TSB broth alone (B, D). Growth curves representing data obtained from at  
679 least three independent experiments are presented. E) Fold change in expression of *copB* and  
680 *mco* in *S. aureus* cultured in TSB vs TSB with copper chloride (4 mM). The  $\Delta\Delta CT$  method  
681 was used to determine the relative expression levels of the *copB* and *mco* genes of 14-2533T  
682 (pSCBU) and its mutants, normalised to *gyrB*. Presented are the means  $\pm$  SD of 3  
683 independent experiments, with statistical significance determined by ANOVA, \*\* $P < 0.05$  \*\*\*  
684  $P < 0.005$ .

685 **Figure 3.** Hypertolerance to copper increases resistance of *S. aureus* to macrophage killing.  
686 Mouse macrophage cell line (RAW264.7) was suspended in DMEM supplemented with  
687 mouse IFN $\gamma$  (40 ng/mL) and Cu<sub>2</sub>SO<sub>4</sub> (40  $\mu$ M) and seeded in 24 well plates at  $2 \times 10^6$  cells

688 per mL for 18h at 37°C in 5% CO<sub>2</sub>. 14-2533T (A) or MRSA252 (B) and derivatives were  
689 grown overnight in RPMI-1640 and then inoculated into the wells at an MOI of 10 in DMEM  
690 allowing phagocytosis for 30 min followed by killing of extracellular bacteria with  
691 gentamycin/lysostaphin for 30 min. Macrophages were then lysed at this time point (T<sub>0</sub>) and  
692 after 3h incubation (T<sub>3h</sub>) and subjected to viable count to determine the levels of bacterial  
693 survival. The CsoR C41A/H66A/C70A expressing mutants are indicated as CHC. Presented  
694 are means ± SD of three independent experiments. Statistical significance is indicated,  
695 \*\*P<0.005 \* P<0.05, ns, not significant.

696 **Figure 4.** Intracellular expression of *copB* and *mco*. Fold change in expression of *copB* and  
697 *mco* by wild-type *S. aureus* relative to CsoR CHC mutants of either 14-2533T (pSCBU) (A)  
698 or MRSA252 (B). RAW264.7 macrophages were activated with IFN $\gamma$  (50  $\mu$ g/mL) and of  
699 copper chloride (40  $\mu$ M) for 18 h. Infections of the macrophage monolayer were performed  
700 with RPMI-grown *S. aureus* at an MOI of 20. Extracellular bacteria were killed by treatment  
701 with with gentamycin/lysostaphin following washing of the monolayers with PBS. 3 h post  
702 infection RNA was isolated from infected macrophages and for to RT-qPCR. The  $\Delta\Delta$ CT  
703 method was used to determine the relative expression levels of *mco* and *copB* in WT and  
704 CHC mutants normalised to *gyrB*. Presented are the means ±SD of 3 independent  
705 experiments, with statistical significance by ANOVA and Bonfferoni's Multiple Comparison  
706 post test; \*P< 0.5 \*\*P<0.05 \*\*\* P<0.005. ns, not significant

707 **Figure 5.** Increased survival of copper hypertolerant *S. aureus* in human blood. *S. aureus* (ca.  
708 1 $\times$ 10<sup>4</sup> CFU/mL) strains were inoculated into freshly drawn human blood (A, B) or plasma  
709 (C, D) and incubated for 3 h at 37°C. Viable count was used to determine the numbers of  
710 bacteria in blood or plasma. The number of CFU after 3 h is expressed as a percentage of the  
711 original input CFU at 0 h. Horizontal lines represent the means ± SD of at least three



712 independent experiments. Statistical significance was determined using ANOVA following  
713 Dunnett's Multiple Comparison Test, \* P= 0.0192 (A) or an unpaired t-test, \*\* P= 0.0052 (B).

714 **Figure 6.** Maximum likelihood trees of CC22, CC30 and CC398 showing distribution of  
715 *copA*, *copB*, *mco*, *copL* genes. Trees are rooted in the longest branch (CC22 to *S. aureus* 08  
716 01492; CC398 to *S. aureus* SO1977; CC30 to *S. aureus* MRSA252). Ring 1, 2, 3 and 4 show  
717 presence of *copA*, *copB*, *mco*, *copL* as blue, purple, yellow, and red.


718

719


**TABLE. 1.** Susceptibility of *S. aureus* strains to metals

Strain	<i>copAZ</i>	<i>copB</i>	<i>mco</i>	MIC <sup>a</sup> Cu <sub>2</sub> SO <sub>4</sub>	<i>cadA</i>	MIC CdCl <sub>2</sub>	MIC ZnCl <sub>2</sub>
14-2533T	ch <sup>b</sup>	NE <sup>c</sup>	NE	6 mM	NE	20 μM	2 mM
14-2533T (pSCBU)	ch	p <sup>d</sup>	p	11 mM	p	20 mM	20 mM
14-2533T pSCBUΔ <i>copB</i>	ch	Δ <sup>e</sup>	p	6 mM	p	20 mM	20 mM
14-2533T pSCBUΔ <i>mco</i>	ch	p	Δ	8 mM	p	20 mM	20 mM
14-2533T CHC	ch	NE	NE	6 mM	NE	20 μM	2 mM
14-2533T CHC pSCBU	ch	p	p	10 mM	p	20 mM	20 mM
MRSA252	ch	ch	ch	8 mM	NE	NT <sup>f</sup>	NT
MRSA252 CHC	ch	ch	ch	5 mM	NE	NT	NT


<sup>a</sup>MIC, minimal inhibitory concentrations determined using a microdilution method, <sup>b</sup>ch, gene is incorporated into the chromosome, <sup>c</sup>NE, gene is not carried by the strain, <sup>d</sup>p, gene is carried on a replicating plasmid, <sup>e</sup>Δ, gene has been deleted by mutation, <sup>f</sup>NT, not tested.




**Figure 1.** Electrophoretic mobility shift assay analysis of recombinant CsoR variants binding to the putative promoters upstream of *copA* ( $P_{copA}$ ), *copB* ( $P_{copB}$ ) and *mco* ( $P_{mco}$ ). A) Schematic representation of *copA-copZ* & *copB-mco* operons with putative promoter sequences. B-D) Recombinant wildtype CsoR<sub>WT</sub> or the CsoR<sub>CHC</sub> mutant (CsoR C41A/H66A/C70A) were purified and tested for binding to PCR products containing the DNA sequences (~200 bp) upstream of the respective start codon, and a control DNA fragment of non-specific DNA sequence (nsDNA). B) Incubation of  $P_{copA}$  DNA with wild type apo-CsoR, but not Cu(I)-CsoR, retards the migration of  $P_{copA}$ . C) CsoR CHC retards migration of  $P_{copA}$  in both the presence and absence of Cu(I). D) CsoR retards migration of  $P_{copA}$  and  $P_{copB}$  but not of  $P_{mco}$ .



**Figure 2.** Enhanced growth in subinhibitory concentrations of copper chloride requires expression of copper tolerance genes. Growth of *S. aureus* 14-2533T and MRSA252 variants was measured in TSB supplemented with sub-inhibitory (4 mM) concentrations of copper chloride (A, C) or TSB broth alone (B, D). Growth curves representing data obtained from at least three independent experiments are presented. E) Fold change in expression of *copB* and *mco* in *S. aureus* cultured in TSB vs TSB with copper chloride (4 mM). The  $\Delta\Delta CT$  method was used to determine the relative expression levels of the *copB* and *mco* genes of 14-2533T (pSCBU) and its mutants, normalised to *gyrB*. Presented are the means  $\pm$  SD of 3 independent experiments, with statistical significance determined by ANOVA, \*\* $P < 0.05$  \*\*\*  $P < 0.005$ .




**Figure 3.** Hypertolerance to copper increases resistance of *S. aureus* to macrophage killing. Mouse macrophage cell line (RAW264.7) was suspended in DMEM supplemented with mouse IFN $\gamma$  (40 ng/mL) and Cu $_2$ SO $_4$  (40  $\mu$ M) and seeded in 24 well plates at  $2 \times 10^6$  cells per mL for 18h at 37°C in 5% CO $_2$ . 14-2533T (A) or MRSA252 (B) and derivatives were grown overnight in RPMI-1640 and then inoculated into the wells at an MOI of 10 in DMEM allowing phagocytosis for 30 min followed by killing of extracellular bacteria with gentamycin/lysostaphin for 30 min. Macrophages were then lysed at this time point (T0) and after 3h incubation (T3h) and subjected to viable count to determine the levels of bacterial survival. The CsoR C41A/H66A/C70A expressing mutants are indicated as CHC. Presented are means  $\pm$  SD of three independent experiments. Statistical significance is indicated, \*\* $P < 0.005$  \*  $P < 0.05$ . ns, not significant.




6

**Figure 4.** Intracellular expression of *copB* and *mco*. Fold change in expression of *copB* and *mco* by wild-type *S. aureus* relative to CsoR CHC mutants of either 14-2533T (pSCBU) (A) or MRSA252 (B). RAW264.7 macrophages were activated with IFN $\gamma$  (50  $\mu\text{g}/\text{mL}$ ) and of copper chloride (40  $\mu\text{M}$ ) for 18 h. Infections of the macrophage monolayer were performed with RPMI-grown *S. aureus* at an MOI of 20. Extracellular bacteria were killed by treatment with gentamycin/lysostaphin following washing of the monolayers with PBS. 3 h post infection RNA was isolated from infected macrophages and for to RT-qPCR. The  $\Delta\Delta\text{CT}$  method was used to determine the relative expression levels of *mco* and *copB* in WT and CHC mutants normalised to *gyrB*. Presented are the means  $\pm$ SD of 3 independent experiments, with statistical significance by ANOVA and Bonfferoni's Multiple Comparison post test; \* $P < 0.5$  \*\* $P < 0.05$  \*\*\*  $P < 0.005$ . ns, not significant



**Figure 5.** Increased survival of copper hypertolerant *S. aureus* in human blood. *S. aureus* (ca.  $1 \times 10^4$  CFU/mL) strains were inoculated into freshly drawn human blood (A, B) or plasma (C, D) and incubated for 3 h at 37°C. Viable count was used to determine the numbers of bacteria in blood or plasma. The number of CFU after 3 h is expressed as a percentage of the original input CFU at 0 h. Horizontal lines represent the means  $\pm$  SD of at least three independent experiments. Statistical significance was determined using ANOVA following Dunnett's Multiple Comparison Test, \*  $P = 0.0192$  (A) or an unpaired t-test, \*\*  $P = 0.0052$  (B).



	CC22	CC30	CC398
<span style="color: blue;">■</span> <i>copA</i>	100%	100%	100%
<span style="color: purple;">■</span> <i>copB</i>	50.88%	85.93%	25.74%
<span style="color: yellow;">■</span> <i>mco</i>	50.88%	85.31%	22.35%
<span style="color: red;">■</span> <i>copL</i>	0.09%	0.62%	52.05%

**Figure 6.** Maximum likelihood trees of CC22, CC30 and CC398 showing distribution of *copA*, *copB*, *mco*, *copL* genes. Trees are rooted in the longest branch (CC22 to *S. aureus* 08 01492; CC398 to *S. aureus* SO1977; CC30 to *S. aureus* MRSA252). Ring 1, 2, 3 and 4 show presence of *copA*, *copB*, *mco*, *copL* as blue, purple, yellow, and red.